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(EuroSCORE) and Society of Thoracic Surgeons (STS) score were
21.6  15.5 and 7.0  5.6, respectively. Rates of death at 30 days and
1 year were 3.4% and 10.6%, respectively. At 30 days, the incidence
of all stroke, major vascular complications, life-threatening
bleeding, and acute kidney injury (stage 2 or 3) were 3.0%, 5.2%, 7.6%
and 4.2%, respectively. Paravalvular regurgitation moderate or
greater occurred 9.5%. Device success rate and combined safety
endpoint at 30 days were 86.2% and 81.0%, respectively. In a multi-
variate model, female, chronic kidney disease, diabetes mellitus,
pulmonary disease, peripheral vascular disease, paravalvular regur-
gitation mild or greater, and STS score were signiﬁcantly associated
with reduced survival.
CONCLUSIONS This registry reﬂects the real-life experience of TAVR
in patients with increased risk in Asian Paciﬁc countries.
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BACKGROUND High surgical risk and inoperable patients with severe
aortic stenosis (AS) undergoing TAVR often have reduced baseline
renal function. The impact of TAVR on improving this reduced base-
line renal function is unknown.
METHODS All patients undergoing TAVR from the PARTNER 1A (high
surgical risk), PARTNER 1B (inoperable), and both the randomized and
non-randomized continued access cohorts with glomerular ﬁltration
rate (GFR, utilizing the modiﬁcation of diet in renal disease formula) 
60 mL/min were analyzed. Patients were categorized as improved
GFR (30-day follow-up GFR 10% higher than baseline pre-TAVR
GFR), worsened GFR (30-day follow-up GFR 10% lower than baseline
pre-TAVR GFR), or no signiﬁcant change (not ﬁtting either previous
group). Baseline characteristics and 1-year all-cause mortality, as well
as repeat hospitalization rates, were compared between groups. Cox
regression models were used to determine multivariable predictors of
all-cause 1-year mortality.
RESULTS In total, 822 patients were analyzed, of which 345 (42%)
showed an improvement in GFR, 197 (24%) had worsening in GFR, and
280 (34%) had no signiﬁcant change in GFR. Comparing patients with
improved GFR with those with worsening GFR and those with no
signiﬁcant change in GFR, there was no difference in the mean age,
BMI, diabetes mellitus, COPD, CAD, PAD, pulmonary hypertension,
renal disease (Cr> 2 mg/dl), NYHA class III or IV symptoms, liver
disease, mean transaortic gradient, mean cardiac index, or mean
baseline EF. The improved GFR group had a greater percentage of
females (55.1% for improved GFR group vs. 40.1% for worsened GFR
group vs. 47.1% for no change group, p<0.01), lower median STS score
(10.9 vs. 11.0 vs. 10.6, p¼ 0.04), and had less smokers (39.4% vs. 54.6%
vs. 48.0%, p<0.01). Adjudicated 1-year all-cause mortality was lower
in the improved GFR group compared to the worsened and no sig-
niﬁcant change groups (15.4% vs. 25.8% vs. 19.1%, p<0.01), as well as
1-year repeat hospitalization (15.1% vs. 30.4 vs. 18.5% %, p<0.01). In a
multivariable analysis, after adjusting for age, gender, BMI, STS score,
diabetes mellitus, COPD, stroke or TIA, baseline ejection fraction,
prior CABG, and baseline GFR, improvement in GFR was associated
with reduced 1-year mortality (HR 0.51, 95% CI 0.34-0.76, p<0.01).
CONCLUSIONS Among those with reduced baseline GFR, TAVR re-
sults in an improvement in GFR in a substantial portion of patients.
Improvement in GFR following TAVR is independently associated
with a reduction in all-cause 1-year mortality in patients with severely
symptomatic AS who are at high surgical risk or are inoperable.
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BACKGROUND The CoreValve self-expanding frame does not require
balloon expansion, but procedural post-dilation of the frame can be
performed in patients with suboptimal acute results. We sought to
deﬁne the incidence of balloon post-dilation (BPD) and the association
